Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 231 to 240 of 875

TitleReference numberPublishedLast updated
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and overTA893
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapyTA895
Bulevirtide for treating chronic hepatitis DTA896
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)TA899
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891
Mosunetuzumab for treating relapsed or refractory follicular lymphomaTA892
Risankizumab for previously treated moderately to severely active Crohn's diseaseTA888
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889

Results per page

  1. 10
  2. 25
  3. 50
  4. All